BioCryst Pharmaceuticals announced that the compensation committee of BioCryst’s board of directors granted 12 newly-hired employees stock options to purchase an aggregate of 178,100 shares, and restricted stock units (RSUs) covering an aggregate of 56,050 shares, of BioCryst common stock. The options and RSUs were granted as of December 30, 2022, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $11.48 per share, which is equal to the closing price of BioCryst common stock on the grant date.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BCRX:
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- BioCryst to Present at 41st Annual J.P. Morgan Healthcare Conference
- BioCryst price target lowered to $10 from $12 at Barclays
- Oppenheimer keeps Perform on BioCryst after discontinuation of BCX9930 program
- Cowen says full sale of BioCryst ‘potentially now even more likely’